A Phase 4, 6-Month Open-Label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Quillichew (Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablets (ERCT) in Children with Attention Deficit Hyperactivity Disorder

Administered By

Awarded By

Contributors

Start/End

  • May 31, 2018 - January 16, 2019